Pharmacodynamics of fluoroquinolones in experimental models of endocarditis

Clinical Infectious Diseases

Volumn 27, Issue 1, 1998, Pages 47-50

  Andes, David R ^a   Craig, William A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; ENOXACIN; FLEROXACIN; LEVOFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEMAFLOXACIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANIMAL MODEL; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; ENDOCARDITIS; ENTEROBACTER AEROGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; TREATMENT OUTCOME;

EID: 0031854524     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514624     Document Type: Conference Paper

References (13)

1. Craig W. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995;14:4-10.
2. Wantanabe Y, Ebert S, Craig W. AUC/MIC ratio is unifying parameter for comparison of in-vivo activity among fiuoroquinolones [abstract no 42]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim, California). Washington, DC: American Society of Microbiology, 1992.
3. Perronne C, Malinvemi R, Glauser M. Treatment of Staphylococcus aureus endocarditis in rats with oumermycin A1 and ciprofloxacin, alone or in combination. Antimicrob Agents Chemother 1987;31:539-43.
4. Kaatz G, Seo S, Barriere S, Albrecht L, Rybak M. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1991;35:1547-50.
5. Kaatz G, Barriere S, Schaberg D, Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother 1987;20:753-8.
6. Rouse M, Wilcox R, Henry N, Stechelberg J, Wilson W. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 1990;34:273-6.
7. Entenza J, Blatter M, Glauser M, Moreillon P. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob Agents Chemother 1994;38:2683-8.
8. Sullam P, Tauber M, Hackbarth C, Chambers H, Scott K, Sande M. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 1985;27:685-7.
9. 14C)temofloxacin in cardiac vegetations. Antimicrob Agents Chemother 1992;36:2216-21.
10. Gilbert M, Boscia J, Kobasa W, Kaye D. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1986;29:461-3.
11. Kaatz G, Seo S, Barriere S, Albrecht, Rybak M. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1989;33:519-21.
12. Kaatz G, Barriere S, Schaberg D, Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1987;31:527-30.
13. Hessen M, Pitsakis P, Kaye D. Oral temofloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990;34:1143-5.